Test is NOT available for Outreach clients (but is available to MMC-Dickinson).
To measure and monitor serum infliximab (IFX) and antibodies-to-infliximab (ATI) levels at any time during therapy.
Send ambient or cold pack. Do not freeze.
Frozen specimens, Whole blood
This test was developed and its performance characteristics determined by Prometheus Laboratories, CAP-accredited (6805501) and CLIA-certified (05D0917432) as qualified to perform high complexity testing. It has not been cleared or approved by the US Food and Drug Administration
The Anser® IFX test is a quantitative therapeutic drug monitoring (TDM) assay that allows healthcare providers to measure and monitor serum infliximab (IFX) and antibodies-to-infliximab (ATI) levels at any time during therapy.
Serum concentrations of infliximab (IFX) may vary among equally dosed patients which can ultimately affect patient outcomes. Suboptimal levels of IFX have been linked to lower response rates in IBD patients. Furthermore, some patients may develop immunogenicity to IFX by producing ATI. The presence of ATI has also been associated with increased rates of infusion reactions and drug clearance leading to lower response rates. Therefore, the quantitative measurement of IFX and ATI levels in serum provides valuable information to healthcare providers to better assess a patient's risk or reason for losing response to IFX and helps them decide an appropriate course of action.
Serum infliximab (IFX) Lower Limit of Quantification: < 1.0 ug/mL
Antibody to infliximab (ATI) Lower Limit of Quantification: < 3.1 U/mL